Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Recruiting · NCT05583071 · Registry updated 2025-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2025-08-13 | NCT05583071 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| University of Cologne | 43 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin | Berlin | Germany | 2 |
| Klinikum Stuttgart - Katharienenhospital | Stuttgart | Germany | 1 |
| University of Cologne | Cologne | Germany | 1 |
| Universitätsklinikum Essen | Essen | Germany | 1 |
| Universitätsklinikum Freiburg | Freiburg im Breisgau | Germany | 1 |
| Universitätsklinikum Hamburg-Eppendorf | Hamburg | Germany | 1 |